Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fluorodeoxyglucose F18 | 39 | 2022 | 1988 | 4.950 |
Why?
|
Inflammatory Breast Neoplasms | 9 | 2021 | 120 | 2.420 |
Why?
|
Radiopharmaceuticals | 36 | 2022 | 2708 | 2.330 |
Why?
|
Positron-Emission Tomography | 42 | 2022 | 6170 | 1.860 |
Why?
|
Organometallic Compounds | 4 | 2022 | 663 | 1.500 |
Why?
|
Radium | 5 | 2020 | 55 | 1.380 |
Why?
|
Neuroendocrine Tumors | 4 | 2022 | 534 | 1.340 |
Why?
|
Octreotide | 4 | 2022 | 155 | 1.190 |
Why?
|
Adipose Tissue, Brown | 4 | 2021 | 810 | 1.110 |
Why?
|
Radioimmunotherapy | 7 | 2013 | 74 | 1.100 |
Why?
|
Tomography, X-Ray Computed | 28 | 2020 | 20308 | 1.070 |
Why?
|
Lymphoma | 7 | 2017 | 1871 | 1.070 |
Why?
|
Bone Neoplasms | 6 | 2020 | 2579 | 1.030 |
Why?
|
Dipeptides | 2 | 2022 | 402 | 0.990 |
Why?
|
Lutetium | 1 | 2022 | 23 | 0.960 |
Why?
|
Heterocyclic Compounds, 1-Ring | 1 | 2022 | 54 | 0.920 |
Why?
|
Receptors, Peptide | 2 | 2022 | 271 | 0.840 |
Why?
|
Dihydrotestosterone | 1 | 2021 | 194 | 0.810 |
Why?
|
Cyclobutanes | 1 | 2020 | 60 | 0.760 |
Why?
|
Ribs | 1 | 2021 | 234 | 0.760 |
Why?
|
Carboxylic Acids | 1 | 2020 | 102 | 0.760 |
Why?
|
Mouth Neoplasms | 2 | 2022 | 564 | 0.740 |
Why?
|
Hematologic Neoplasms | 2 | 2021 | 1687 | 0.700 |
Why?
|
Diagnostic Imaging | 5 | 2017 | 3495 | 0.590 |
Why?
|
Nuclear Medicine | 3 | 2018 | 228 | 0.560 |
Why?
|
Carcinoma, Lobular | 1 | 2020 | 482 | 0.560 |
Why?
|
Molecular Imaging | 2 | 2012 | 853 | 0.520 |
Why?
|
Hodgkin Disease | 3 | 2017 | 1412 | 0.520 |
Why?
|
Patient Care Planning | 1 | 2020 | 933 | 0.520 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2021 | 8877 | 0.480 |
Why?
|
Radioisotopes | 5 | 2022 | 509 | 0.470 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1086 | 0.450 |
Why?
|
Stem Cell Transplantation | 2 | 2021 | 1660 | 0.450 |
Why?
|
Radionuclide Imaging | 5 | 2022 | 2028 | 0.440 |
Why?
|
Radiotherapy | 3 | 2018 | 1623 | 0.440 |
Why?
|
Blood Glucose | 3 | 2018 | 6255 | 0.430 |
Why?
|
Parathyroid Neoplasms | 2 | 2010 | 243 | 0.430 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 5112 | 0.420 |
Why?
|
Head and Neck Neoplasms | 3 | 2022 | 2591 | 0.400 |
Why?
|
Colon | 1 | 2019 | 1762 | 0.400 |
Why?
|
Carcinoma | 5 | 2021 | 2307 | 0.400 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 3 | 2009 | 1178 | 0.360 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2022 | 3876 | 0.360 |
Why?
|
Antibodies, Monoclonal | 6 | 2017 | 9584 | 0.360 |
Why?
|
Humans | 94 | 2022 | 708843 | 0.350 |
Why?
|
Genital Neoplasms, Female | 1 | 2014 | 510 | 0.350 |
Why?
|
Radiometry | 5 | 2021 | 823 | 0.350 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 1333 | 0.330 |
Why?
|
Neck Muscles | 1 | 2007 | 105 | 0.320 |
Why?
|
Hyperparathyroidism | 1 | 2008 | 340 | 0.320 |
Why?
|
Neoplasms | 11 | 2018 | 20172 | 0.320 |
Why?
|
Breast Neoplasms | 6 | 2022 | 19800 | 0.320 |
Why?
|
Prostatic Neoplasms | 3 | 2022 | 10525 | 0.320 |
Why?
|
Immunotherapy | 3 | 2022 | 4057 | 0.310 |
Why?
|
Retrospective Studies | 27 | 2022 | 71483 | 0.310 |
Why?
|
Neoplasm Staging | 9 | 2021 | 11126 | 0.310 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 3970 | 0.310 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2021 | 5135 | 0.300 |
Why?
|
Diagnosis, Differential | 9 | 2020 | 13274 | 0.290 |
Why?
|
Transplantation, Autologous | 3 | 2021 | 2092 | 0.290 |
Why?
|
Intercostal Muscles | 1 | 2004 | 25 | 0.280 |
Why?
|
Prostate-Specific Antigen | 3 | 2022 | 2245 | 0.270 |
Why?
|
Lymphatic Diseases | 1 | 2006 | 330 | 0.260 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2020 | 11253 | 0.260 |
Why?
|
Tissue Distribution | 5 | 2019 | 2428 | 0.250 |
Why?
|
Adult | 38 | 2021 | 211041 | 0.250 |
Why?
|
Middle Aged | 45 | 2021 | 213752 | 0.240 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2006 | 637 | 0.240 |
Why?
|
Treatment Outcome | 19 | 2022 | 61932 | 0.240 |
Why?
|
Aged | 39 | 2022 | 161488 | 0.240 |
Why?
|
Neck | 1 | 2007 | 698 | 0.230 |
Why?
|
Female | 50 | 2022 | 375205 | 0.230 |
Why?
|
Adenoma | 2 | 2010 | 2130 | 0.230 |
Why?
|
Head | 1 | 2007 | 845 | 0.220 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 2951 | 0.220 |
Why?
|
Taxoids | 2 | 2022 | 655 | 0.210 |
Why?
|
Subtraction Technique | 1 | 2004 | 543 | 0.210 |
Why?
|
Male | 43 | 2022 | 349524 | 0.210 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2017 | 1829 | 0.210 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 917 | 0.210 |
Why?
|
Paraganglioma | 1 | 2022 | 146 | 0.200 |
Why?
|
Radiotherapy Dosage | 6 | 2021 | 2927 | 0.200 |
Why?
|
Mastectomy | 4 | 2021 | 1680 | 0.200 |
Why?
|
Pheochromocytoma | 1 | 2022 | 339 | 0.190 |
Why?
|
Education, Medical | 1 | 2012 | 1683 | 0.190 |
Why?
|
Receptors, Progesterone | 3 | 2020 | 1108 | 0.190 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 632 | 0.190 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 1568 | 0.190 |
Why?
|
Cholecystokinin | 1 | 2019 | 119 | 0.180 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2019 | 138 | 0.180 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2018 | 3515 | 0.180 |
Why?
|
Thyroid Neoplasms | 2 | 2009 | 2219 | 0.180 |
Why?
|
Survival Analysis | 4 | 2021 | 10507 | 0.170 |
Why?
|
Body Weight | 1 | 2009 | 4680 | 0.170 |
Why?
|
Gallbladder | 1 | 2019 | 307 | 0.170 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2020 | 211 | 0.170 |
Why?
|
Receptors, Somatostatin | 1 | 2018 | 125 | 0.170 |
Why?
|
Parathyroid Glands | 2 | 2010 | 519 | 0.160 |
Why?
|
Aged, 80 and over | 20 | 2020 | 58184 | 0.160 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2017 | 919 | 0.160 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2017 | 991 | 0.160 |
Why?
|
Crohn Disease | 1 | 2009 | 2277 | 0.150 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2022 | 731 | 0.150 |
Why?
|
Axilla | 1 | 2018 | 534 | 0.150 |
Why?
|
Receptor, erbB-2 | 4 | 2020 | 2307 | 0.150 |
Why?
|
Whole-Body Irradiation | 1 | 2017 | 459 | 0.150 |
Why?
|
Hepatitis C | 1 | 2006 | 1493 | 0.150 |
Why?
|
Oncology Service, Hospital | 1 | 2016 | 59 | 0.150 |
Why?
|
Uveal Neoplasms | 1 | 2018 | 317 | 0.150 |
Why?
|
Intestinal Neoplasms | 2 | 2018 | 300 | 0.140 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13714 | 0.140 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 470 | 0.140 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2012 | 1330 | 0.140 |
Why?
|
Beta Particles | 1 | 2015 | 54 | 0.140 |
Why?
|
Artifacts | 2 | 2018 | 1904 | 0.140 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2009 | 680 | 0.130 |
Why?
|
Neoadjuvant Therapy | 4 | 2020 | 2561 | 0.130 |
Why?
|
Prognosis | 5 | 2021 | 28919 | 0.130 |
Why?
|
Receptors, Estrogen | 2 | 2020 | 2144 | 0.130 |
Why?
|
Internship and Residency | 2 | 2012 | 5556 | 0.130 |
Why?
|
Prostate | 1 | 2022 | 1564 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 813 | 0.130 |
Why?
|
Genes, Retinoblastoma | 1 | 2014 | 139 | 0.130 |
Why?
|
Remission Induction | 2 | 2017 | 2399 | 0.130 |
Why?
|
Neoplasm, Residual | 4 | 2017 | 996 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 9488 | 0.120 |
Why?
|
Sensitivity and Specificity | 7 | 2010 | 14836 | 0.120 |
Why?
|
Triazoles | 1 | 2018 | 910 | 0.120 |
Why?
|
Lymphoma, Follicular | 2 | 2013 | 405 | 0.120 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1179 | 0.120 |
Why?
|
Combined Modality Therapy | 6 | 2021 | 8896 | 0.110 |
Why?
|
Vascular Neoplasms | 1 | 2014 | 182 | 0.110 |
Why?
|
Radiology Department, Hospital | 1 | 2016 | 413 | 0.110 |
Why?
|
Ultrasonography, Mammary | 1 | 2013 | 248 | 0.110 |
Why?
|
Sirolimus | 2 | 2009 | 1571 | 0.100 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39038 | 0.100 |
Why?
|
Vena Cava, Inferior | 1 | 2014 | 444 | 0.100 |
Why?
|
Bone Marrow | 3 | 2010 | 2938 | 0.100 |
Why?
|
Radiation Dosage | 2 | 2017 | 2041 | 0.100 |
Why?
|
Vaccination | 1 | 2022 | 2864 | 0.100 |
Why?
|
Leiomyosarcoma | 1 | 2014 | 455 | 0.100 |
Why?
|
Bone Marrow Neoplasms | 1 | 2010 | 108 | 0.090 |
Why?
|
Mammaplasty | 1 | 2019 | 1126 | 0.090 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 622 | 0.090 |
Why?
|
Glucose | 1 | 2022 | 4261 | 0.090 |
Why?
|
Epithelial Cells | 1 | 2022 | 3690 | 0.090 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 272 | 0.090 |
Why?
|
Oxygen Radioisotopes | 1 | 2008 | 78 | 0.090 |
Why?
|
Cold Temperature | 2 | 2010 | 789 | 0.090 |
Why?
|
Fibrous Dysplasia of Bone | 1 | 2008 | 47 | 0.090 |
Why?
|
Rats, Inbred Lew | 2 | 2010 | 1154 | 0.090 |
Why?
|
Ovarian Neoplasms | 2 | 2021 | 4712 | 0.090 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2008 | 192 | 0.090 |
Why?
|
Bronchial Neoplasms | 1 | 2008 | 109 | 0.090 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2010 | 147 | 0.080 |
Why?
|
Molecular Mimicry | 1 | 2008 | 201 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2010 | 243 | 0.080 |
Why?
|
Hypertrophy | 1 | 2009 | 579 | 0.080 |
Why?
|
Intestinal Mucosa | 1 | 2019 | 3070 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2340 | 0.080 |
Why?
|
Benzamides | 1 | 2013 | 1406 | 0.080 |
Why?
|
Hematopoiesis, Extramedullary | 1 | 2007 | 65 | 0.080 |
Why?
|
Smoking | 1 | 2004 | 8612 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 952 | 0.080 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5266 | 0.080 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2013 | 682 | 0.080 |
Why?
|
Hematologic Diseases | 1 | 2010 | 489 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3490 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2016 | 1578 | 0.080 |
Why?
|
Mastectomy, Modified Radical | 2 | 2017 | 59 | 0.080 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2007 | 443 | 0.080 |
Why?
|
Survival Rate | 5 | 2017 | 13202 | 0.080 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7487 | 0.080 |
Why?
|
Population Surveillance | 1 | 2017 | 2606 | 0.080 |
Why?
|
Filgrastim | 1 | 2006 | 135 | 0.080 |
Why?
|
Disease-Free Survival | 5 | 2017 | 7026 | 0.070 |
Why?
|
Constriction, Pathologic | 1 | 2009 | 1028 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2013 | 1228 | 0.070 |
Why?
|
Risk | 1 | 2018 | 9641 | 0.070 |
Why?
|
Laboratories | 1 | 2009 | 430 | 0.070 |
Why?
|
Metabolic Clearance Rate | 1 | 2006 | 401 | 0.070 |
Why?
|
Hormones | 2 | 2022 | 855 | 0.070 |
Why?
|
Contrast Media | 1 | 2019 | 5267 | 0.070 |
Why?
|
Pyrimidines | 2 | 2018 | 2950 | 0.070 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2009 | 308 | 0.070 |
Why?
|
Thyrotropin | 1 | 2009 | 820 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2779 | 0.070 |
Why?
|
Drug Evaluation | 1 | 2006 | 661 | 0.070 |
Why?
|
Arteries | 1 | 2010 | 1131 | 0.070 |
Why?
|
Muscles | 1 | 2009 | 1622 | 0.070 |
Why?
|
Young Adult | 6 | 2017 | 55940 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1496 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6765 | 0.060 |
Why?
|
Bleomycin | 2 | 2017 | 503 | 0.060 |
Why?
|
Skull | 1 | 2008 | 816 | 0.060 |
Why?
|
Thrombocytopenia | 2 | 2010 | 1136 | 0.060 |
Why?
|
Hernia, Inguinal | 1 | 2005 | 190 | 0.060 |
Why?
|
Pelvic Neoplasms | 1 | 2005 | 246 | 0.060 |
Why?
|
Time Factors | 5 | 2019 | 41038 | 0.060 |
Why?
|
Vinblastine | 2 | 2017 | 505 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2018 | 2910 | 0.060 |
Why?
|
Doxorubicin | 3 | 2017 | 2235 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12447 | 0.060 |
Why?
|
Observer Variation | 1 | 2009 | 2687 | 0.060 |
Why?
|
Piperazines | 1 | 2013 | 2532 | 0.060 |
Why?
|
Mammography | 1 | 2013 | 2442 | 0.060 |
Why?
|
Aromatase Inhibitors | 1 | 2006 | 503 | 0.060 |
Why?
|
Kinetics | 3 | 2021 | 6796 | 0.060 |
Why?
|
Patient Care Team | 1 | 2013 | 2587 | 0.050 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 5045 | 0.050 |
Why?
|
Succinate Dehydrogenase | 1 | 2022 | 159 | 0.050 |
Why?
|
Dacarbazine | 2 | 2017 | 585 | 0.050 |
Why?
|
Surgery, Computer-Assisted | 1 | 2010 | 1018 | 0.050 |
Why?
|
Protein Kinases | 1 | 2009 | 1680 | 0.050 |
Why?
|
Thoracic Vertebrae | 1 | 2006 | 613 | 0.050 |
Why?
|
Tamoxifen | 1 | 2006 | 989 | 0.050 |
Why?
|
Organ Specificity | 1 | 2006 | 2064 | 0.050 |
Why?
|
Phantoms, Imaging | 1 | 2009 | 2401 | 0.050 |
Why?
|
Melanoma | 1 | 2018 | 5194 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2006 | 1399 | 0.050 |
Why?
|
Polyethylene Glycols | 1 | 2006 | 1198 | 0.050 |
Why?
|
Technetium Tc 99m Lidofenin | 1 | 2019 | 3 | 0.050 |
Why?
|
Abdomen | 1 | 2006 | 1094 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 6 | 2021 | 34151 | 0.050 |
Why?
|
Adenocarcinoma | 2 | 2008 | 6338 | 0.050 |
Why?
|
Spleen | 1 | 2006 | 2473 | 0.050 |
Why?
|
Risk Factors | 3 | 2018 | 69553 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2009 | 2593 | 0.050 |
Why?
|
Recombinant Proteins | 2 | 2009 | 6850 | 0.050 |
Why?
|
Forecasting | 1 | 2009 | 2941 | 0.050 |
Why?
|
Societies, Medical | 1 | 2012 | 3776 | 0.050 |
Why?
|
Monte Carlo Method | 3 | 2010 | 1301 | 0.050 |
Why?
|
Radioactive Tracers | 1 | 2019 | 81 | 0.050 |
Why?
|
Cyclophosphamide | 2 | 2017 | 2189 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 2017 | 2303 | 0.040 |
Why?
|
Consent Forms | 1 | 2018 | 50 | 0.040 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 726 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2007 | 1117 | 0.040 |
Why?
|
Reoperation | 1 | 2008 | 4159 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12292 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 5041 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2009 | 19423 | 0.040 |
Why?
|
Spinal Neoplasms | 1 | 2006 | 837 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 8024 | 0.040 |
Why?
|
Cytarabine | 1 | 2020 | 689 | 0.040 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2006 | 1521 | 0.040 |
Why?
|
Disease Progression | 4 | 2016 | 13298 | 0.040 |
Why?
|
Treatment Failure | 2 | 2015 | 2680 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2010 | 914 | 0.040 |
Why?
|
Pilot Projects | 2 | 2009 | 7994 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2015 | 8776 | 0.040 |
Why?
|
Recurrence | 1 | 2008 | 8255 | 0.040 |
Why?
|
Indazoles | 1 | 2018 | 292 | 0.040 |
Why?
|
Tissue Extracts | 1 | 2016 | 147 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 2007 | 2535 | 0.040 |
Why?
|
Acute Disease | 1 | 2006 | 7158 | 0.040 |
Why?
|
Anthracyclines | 1 | 2017 | 254 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2010 | 4044 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 129 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2008 | 3418 | 0.030 |
Why?
|
Cohort Studies | 1 | 2017 | 39292 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2018 | 592 | 0.030 |
Why?
|
Nausea | 1 | 2017 | 654 | 0.030 |
Why?
|
Radiology | 1 | 2007 | 1931 | 0.030 |
Why?
|
Rats | 2 | 2010 | 25094 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2017 | 963 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2006 | 4226 | 0.030 |
Why?
|
Biological Transport | 1 | 2017 | 2146 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 586 | 0.030 |
Why?
|
Animals | 4 | 2015 | 170486 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2009 | 5348 | 0.030 |
Why?
|
Body Mass Index | 1 | 2009 | 12366 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 11239 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2010 | 6497 | 0.030 |
Why?
|
Urinary Tract | 1 | 2013 | 287 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2015 | 567 | 0.030 |
Why?
|
Models, Biological | 1 | 2008 | 9907 | 0.030 |
Why?
|
B-Lymphocyte Subsets | 1 | 2012 | 250 | 0.030 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2012 | 166 | 0.030 |
Why?
|
Vincristine | 1 | 2012 | 1039 | 0.020 |
Why?
|
Yttrium Radioisotopes | 1 | 2010 | 101 | 0.020 |
Why?
|
Inflammation | 1 | 2009 | 10019 | 0.020 |
Why?
|
Pharyngeal Neoplasms | 1 | 2009 | 90 | 0.020 |
Why?
|
Necrosis | 1 | 2013 | 1646 | 0.020 |
Why?
|
Tonsillar Neoplasms | 1 | 2009 | 52 | 0.020 |
Why?
|
Absorption | 1 | 2009 | 279 | 0.020 |
Why?
|
Stomach Neoplasms | 1 | 2018 | 1214 | 0.020 |
Why?
|
Predictive Value of Tests | 3 | 2010 | 15252 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6766 | 0.020 |
Why?
|
Leucovorin | 1 | 2010 | 598 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 431 | 0.020 |
Why?
|
Glucose Transporter Type 1 | 1 | 2009 | 189 | 0.020 |
Why?
|
Sulfonamides | 1 | 2018 | 1938 | 0.020 |
Why?
|
Clone Cells | 1 | 2012 | 1767 | 0.020 |
Why?
|
Tongue Neoplasms | 1 | 2009 | 172 | 0.020 |
Why?
|
Adolescent | 4 | 2012 | 84718 | 0.020 |
Why?
|
Platelet Count | 1 | 2010 | 794 | 0.020 |
Why?
|
Prednisone | 1 | 2012 | 1556 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2013 | 834 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 871 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2010 | 1670 | 0.020 |
Why?
|
Fluorine Radioisotopes | 1 | 2010 | 460 | 0.020 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2012 | 534 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2017 | 8968 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2012 | 1241 | 0.020 |
Why?
|
Pedigree | 1 | 2014 | 4724 | 0.020 |
Why?
|
Fluorouracil | 1 | 2010 | 1620 | 0.020 |
Why?
|
Methotrexate | 1 | 2012 | 1708 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 2008 | 731 | 0.020 |
Why?
|
Spinal Cord | 1 | 2013 | 1831 | 0.020 |
Why?
|
Thorax | 1 | 2007 | 512 | 0.020 |
Why?
|
Models, Statistical | 2 | 2010 | 5034 | 0.020 |
Why?
|
Fatigue | 1 | 2012 | 1450 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2008 | 1468 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1148 | 0.020 |
Why?
|
Quinazolines | 1 | 2010 | 1420 | 0.020 |
Why?
|
Internationality | 1 | 2009 | 1002 | 0.020 |
Why?
|
World Health Organization | 1 | 2009 | 1261 | 0.020 |
Why?
|
Thyroidectomy | 1 | 2009 | 892 | 0.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 1264 | 0.010 |
Why?
|
Bone and Bones | 1 | 2013 | 2567 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9402 | 0.010 |
Why?
|
Water | 1 | 2008 | 1323 | 0.010 |
Why?
|
Mice, Nude | 1 | 2009 | 3859 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2008 | 1719 | 0.010 |
Why?
|
Lung Diseases | 1 | 2012 | 1889 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 4930 | 0.010 |
Why?
|
Temporal Lobe | 1 | 2008 | 1655 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2004 | 12183 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2010 | 1999 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2009 | 3714 | 0.010 |
Why?
|
Linear Models | 1 | 2010 | 5986 | 0.010 |
Why?
|
Biomedical Research | 1 | 2016 | 3266 | 0.010 |
Why?
|
Child | 1 | 2007 | 73636 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11790 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2009 | 2118 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2005 | 1470 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2016 | 5044 | 0.010 |
Why?
|
Preoperative Care | 1 | 2007 | 2357 | 0.010 |
Why?
|
Neutrophils | 1 | 2010 | 3867 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29262 | 0.010 |
Why?
|
Data Collection | 1 | 2007 | 3276 | 0.010 |
Why?
|
Phosphorylation | 1 | 2009 | 8720 | 0.010 |
Why?
|
Patient Selection | 1 | 2009 | 4306 | 0.010 |
Why?
|
Software | 1 | 2010 | 4345 | 0.010 |
Why?
|
Quality of Life | 1 | 2016 | 11594 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 5197 | 0.010 |
Why?
|
Lung | 1 | 2013 | 9706 | 0.010 |
Why?
|
Computer Simulation | 1 | 2008 | 6048 | 0.010 |
Why?
|
Genetic Variation | 1 | 2009 | 6666 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 10803 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2009 | 16959 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13647 | 0.010 |
Why?
|
Brain | 1 | 2013 | 24969 | 0.000 |
Why?
|
Mice | 1 | 2009 | 80876 | 0.000 |
Why?
|
United States | 1 | 2007 | 67165 | 0.000 |
Why?
|